AMBUJACEM - Swing Trade Analysis with AI Signals
Back to List📊 Swing Trade Rating: 3.7
| Stock Code | AMBUJACEM | Market Cap | 1,10,574 Cr. | Current Price | 445 ₹ | High / Low | 625 ₹ |
| Stock P/E | 28.5 | Book Value | 213 ₹ | Dividend Yield | 0.45 % | ROCE | 3.25 % |
| ROE | 7.67 % | Face Value | 2.00 ₹ | DMA 50 | 461 ₹ | DMA 200 | 515 ₹ |
| Chg in FII Hold | 0.03 % | Chg in DII Hold | -0.02 % | PAT Qtr | 1,742 Cr. | PAT Prev Qtr | -59.2 Cr. |
| RSI | 47.6 | MACD | 0.60 | Volume | 1,29,81,016 | Avg Vol 1Wk | 50,71,142 |
| Low price | 394 ₹ | High price | 625 ₹ | PEG Ratio | 2.14 | Debt to equity | 0.02 |
| 52w Index | 22.2 % | Qtr Profit Var | 214 % | EPS | 14.4 ₹ | Industry PE | 30.4 |
AMBUJACEM shows moderate potential for swing trading. The stock is currently priced at ₹445, below both its 50 DMA (₹461) and 200 DMA (₹515), indicating short-term weakness and medium-term resistance. RSI at 47.6 suggests neutral momentum, while MACD is slightly positive, hinting at a possible recovery. Volumes are significantly higher than the weekly average, showing strong market activity. Fundamentals are decent, though ROCE is relatively weak.
✅ Optimal Entry Price: Around ₹430–₹440 (near support levels)
📤 Exit Strategy: If already holding, consider booking profits near ₹480–₹500, or exit if price falls below ₹420 support.
👍 Positive
- Strong quarterly PAT recovery (₹1,742 Cr vs -₹59.2 Cr)
- EPS of ₹14.4 indicates profitability
- Low debt-to-equity ratio (0.02)
- PEG ratio of 2.14 suggests growth potential
⚠️ Limitation
- ROCE is weak at 3.25%
- Stock trading below both 50 DMA and 200 DMA
- Dividend yield is modest (0.45%)
📉 Company Negative News
- Institutional investors slightly reduced holdings (FII +0.03%, DII -0.02%)
- Stock has fallen ~22% from 52-week high (₹625)
📈 Company Positive News
- Quarterly profit variation surged 214%
- Strong rebound from 52-week low (₹394)
- MACD indicates potential bullish crossover
🏭 Industry
- Industry P/E is 30.4, slightly higher than company’s P/E of 28.5
- Cement sector demand remains steady with infrastructure growth
✅ Conclusion
AMBUJACEM is showing signs of recovery with strong quarterly profits and reasonable valuation compared to industry peers. However, weak ROCE and resistance at higher levels suggest cautious trading. Entry near ₹430–₹440 is favorable, with profit booking around ₹480–₹500. Traders should monitor volume and RSI trends for confirmation of momentum.